Earendil Labs, a global leader in AI-driven biologics discovery, announced a strategic collaboration with Sanofi to develop bispecific antibodies targeting autoimmune and inflammatory diseases. Under the agreement, Sanofi will oversee the development and worldwide commercialization of bispecific candidates discovered through Earendil’s platform. The deal is subject to standard closing conditions and includes significant financial terms designed to support both early-stage research and long-term commercial success.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
As part of the collaboration, Earendil Labs will receive up to $160 million in upfront and near-term payments linked to early program milestones. The total potential value of the partnership, including development and commercial milestones, could reach $2.56 billion. In addition, Earendil will earn tiered royalties on net product sales reaching up to low double-digit percentages.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
Jian Peng, PhD, CEO of Earendil Labs, emphasized that the collaboration expands the application of Earendil’s discovery platform across a broader set of autoimmune disease targets. He explained that combining AI-driven protein modeling with high-throughput experimental validation allows the company to identify and optimize bispecific antibody candidates with greater efficiency and precision. Dr. Peng noted that the partnership reflects Earendil’s commitment to advancing next-generation therapeutics capable of setting new standards of care.
Zhenping Zhu, MD, PhD, President and Co-CEO of Earendil Labs, highlighted the unmet need in autoimmune diseases, where patients often require lifelong treatment and current therapies may be insufficient. He said that partnering with Sanofi’s expertise in clinical development and global commercialization will help accelerate the translation of Earendil’s platform-enabled candidates into potentially transformative medicines, bringing new treatment options to patients worldwide.
This collaboration reinforces both companies’ dedication to leveraging cutting-edge technology and global experience to address the challenges of autoimmune diseases and improve outcomes for patients in need.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
